Novel Microbiome Therapeutics

About Us

ImmuneBiotech AB discovers and develops novel microbiome therapeutics based on probiotic lactic acid bacteria and synbiotic formulations targeting the gut microbiota and the immune system.

There is growing evidence on the importance of the gut microbiota in several challenging diseases, now translating to a new class of microbiome targeting therapeutics, sometime called pharmabiotics or immunobiotics. ImmuneBiotech is one of the forerunners in this field. We have a platform consisting of a library of unique strains of probiotic lactobacilli and also the technologies to select for strains with optimal immunomodulatory functions and the know-how to design novel therapeutic bacterial combinations for use in specific diseases. The company has a pre-clinical stage pipeline of therapeutic lactobacilli combinations for the treatments of chronic inflammatory and infectious diseases.


Our team is driven by innovative spirit combined with solid science, and a passion for translating probiotics into therapeutics. Our vision is to achieve international recognition for excellence of research in the microbiota based therapeutic community, and to be at the forefront in generating and using new knowledge for creating cost-efficient therapies with a true impact on peoples health.


Shahram Lavasani

Shahram Lavasani Ph.D.

Founder, CEO/CSO

Shahram holds a Ph.D. degree from Lund University in Medical Inflammation Research. He is a skillful immunologists with many years of research expertise on gastrointestinal complications in autoimmune and chronic inflammatory diseases. Focusing on Brain-Gut axis he has pioneered research in multiple sclerosis (MS: brain inflammation) by targeting the gut using combination of probiotic bacteria. Shahram has collected new probiotic bacteria from innovative biological sources and developed the proprietary lactobacilli library and has solid know-how in the scientific selection methods (in vitro & in vivo) and combination of strains to achieve optimal therapeutic potential. He has designed ImmuneBiotech’s drug candidates by careful and multiple selection methods to identify potential strains and formulations for the optimal therapeutic management of the diseases.


Shahram Lavasani

Mehrnaz Nouri Ph.D.

Co-founder, Project leader

Mehrnaz holds a Ph.D. degree in Immunology from Lund University. She is an expert in the field of biotechnology and probiotic research. She has patented several strains of lactobacilli and developed a novel vaccination against Salmonella infection. Mehrnaz has contributed with her excellent scientific skills and specific know-how to the development of the ImmuneBiotech’s proprietary lactobacilli library.


Karin Larsson

Karin Larsson Ph.D.

CBO and Project Manager

Karin has a Ph.D. in Biotechnology, Lund University and a Diploma in Marketing management, EFL, School of Economics and Management, Lund University. She has twenty years experience in the Pharma and Life-Science industry and more than ten years experience in Business Development, working in both small and large organization including Novo Nordisk A/S, (now Novozymes), Bioglan AB and Alligator Bioscience AB. Karin is a co-founder and co-owner of the consultancy company Vetenskaps Fabriken AB.


Tobias Andersson

Tobias Andersson MD, Ph.D.

Clinical Research Consultant

Tobias earned his medical degree from the Umeå University. He is a consultant in General Surgery and a major expert in medical examination and diagnosis of gastrointestinal disorders. He has experience of planning, management, and conducting of clinical research trials with industrial collaborator. Tobias is the founder and CEO of Toutatis AB which offer private medical care and occupational health assessments in Sweden. He is also the Chairman and surgeon at the Ellenbogen Medical Center in Malmö.


Gregory Batcheller

Gregory Batcheller, LL.M, J.D., B.Sc. (Econ)

Executive chairman and strategic advisor

Greg brings a strong track record from his positions in the life science industry as an executive decision maker, company founder, and commercial lawyer. He was CEO of DuoCort, chair of Neurovive Pharmaceutical AB, co-founded Laccure, and is a Partner at P.U.L.S.. He is the chair of Monocl AB, Xintela AB, SAGA Diagnostics and director of Business Research Life Sciences Ltd (United Kingdom).


Physician Advisory Board

ImmuneBiotech works closely with physicians that are experts in the fields of infectious diseases, gastroenterology and autoimmunity.